Kainos Laboratories

Kainos Laboratories PEG

Delisted

The PEG Ratio (Price/Earnings-to-Growth) of Kainos Laboratories (4556.T) as of Oct 29, 2026 is 1.88. In the previous year, PEG Ratio (Price/Earnings-to-Growth) was 1.88 — a change of -0.48% (lower).

PEG

1.88

YoY

-0.48%

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Kainos Laboratories is 2025 1.88 . PEG Ratio (Price/Earnings-to-Growth) of Kainos Laboratories was 2024 1.88 . It decreases by -0.48% lower compared to the previous year.

The Kainos Laboratories PEG history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PEG
Date
PEG
Jan 1, 2018
4.32 JPY
Jan 1, 2019
3.11 JPY
Jan 1, 2020
3.02 JPY
Jan 1, 2021
2.88 JPY
Jan 1, 2022
2.35 JPY
Jan 1, 2023
2.12 JPY
Jan 1, 2024
1.88 JPY
Jan 1, 2025
1.88 JPY
The Kainos Laboratories PEG history
YEARPEGYoY
1.88-0.48%
1.88-10.94%
2.12-9.83%
2.35-18.53%
2.88-4.51%
3.02-3.16%
3.11-27.99%
4.32+11.47%
3.88-4.35%
4.06-22.29%
5.22-16.18%
6.23—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kainos Laboratories Stock analysis

What does Kainos Laboratories do? Kainos Laboratories Inc develops and manufactures pharmaceuticals, diagnostic reagents, and related chemical products for distribution and import/export. The company sells its products to healthcare providers, hospitals, and medical institutions within Japan and internationally. Its core offerings include prescription medications, diagnostic tools, and chemical compounds used in medical research and treatment. The business model relies on direct sales to medical facilities and global trade of its pharmaceutical and diagnostic solutions. Kainos Laboratories Inc focuses on the Japanese market with its headquarters in Bunkyo-Ku, Tokyo-To, while also engaging in international import/export activities. The company's revenue streams come from the sale of pharmaceuticals, diagnostic reagents, and chemical products to healthcare professionals and institutions. Its product portfolio targets medical practitioners and research organizations requiring specialized diagnostic and therapeutic solutions. The company operates with 144 full-time employees dedicated to the development, manufacturing, and distribution of its products. Kainos Laboratories Inc generates income through the commercialization of its pharmaceuticals and diagnostic reagents, serving both domestic and global clients in the healthcare sector. Sales are driven by demand for medical treatments and diagnostic tools in clinical and research settings. Kainos Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kainos Laboratories stock

PEG Ratio (Price/Earnings-to-Growth) of Kainos Laboratories is 1.88 in 2025.

PEG Ratio (Price/Earnings-to-Growth) of Kainos Laboratories changed from 1.88 to 1.88, representing a -0.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Kainos Laboratories since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Kainos Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Kainos Laboratories

All Key Metrics — Kainos Laboratories